跳至主要内容
临床试验/NL-OMON21811
NL-OMON21811招募中不适用

Effect of Iron Deficiency on skeletal muscle metabolism in HFpEF

Vifor pharma0 个研究点目标入组 78 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
78

研究概览

简要总结

one

研究设计

研究类型
Observational

入排标准

入选标准

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • Group I HFpEF with iron deficiency
  • Group II HFpEF without iron deficiency
  • HFpEF: according to the ESC guidelines
  • (1) Signs and/or symptoms of heart failure,
  • (2) LVEF = 50%,
  • (3) Elevated levels of natriuretic peptide (NT-proBNP > 125 pg/ml
  • ~ 15 pmol/L)
  • (4) one of the following additional criteria
  • a)Relevant structural heart disease; LV hypertrophy, (LVmass index > 95 g/m2 in women, or >115 g/m2 in men) and/or LA enlargement (LA volume index >34 l/m2)
  • b)Diastolic dysfunction (E/e’ = 13, mean e’ septal and lateral wall < 9 cm/s)
  • Iron deficiency: serum ferritin < 100 µg/L or serum ferritin between 100-299 µg/L in combination with a transferrin saturation < 20%.

排除标准

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • -Reproductive age women
  • -Any iron supplement (oral, iv) during the last 6 months prior to inclusion
  • -Any chemotherapy in last year
  • -Significant peripheral artery disease
  • -Contraindication for CMR
  • ODIN protocol:
  • Uitvoering van MRI onderzoek bij patiënten met een cardiaal implanteerbaar elektronisch device (CIED), waaronder een pacemaker en ICD”
  • ODIN protocol:
  • Voorbereiding klinische patiënten voor MRI onderzoek”
  • Metallic implant (vascular clip, neuro-stimulator, cochlear implant)
  • Pacemaker or implantable cardiac defibrillator(ICD)
  • Claustrophobia
  • -Body weight > 130kg

研究者

发起方
Vifor pharma

相似试验